Sanofi is shelling out $1.15 billion to accumulate Vicebio, a startup with a pipeline of respiratory vaccine candidates and a platform know-how that can help the pharmaceutical big’s ambitions to broaden its portfolio with vaccines able to addressing two or extra pathogens with a single shot.
Past the upfront cost, the deal introduced Tuesday places Vicebio in line to obtain as much as $450 million extra tied to the achievement of growth and regulatory milestones that weren’t specified. Probably the most superior Vicebio program, VXB-241, is a bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in Part 1 growth.
The present strategy to vaccination in opposition to respiratory ailments is a single shot for every pathogen. As extra vaccines turn out to be out there for extra pathogens, the rising variety of pictures turns into formidable to sufferers. London-based Vicebio is creating multivalent vaccines that might pose much less of a burden. Apart from VXB-241, which is being examined in in older adults, the Vicebio pipeline additionally consists of VXB-251, which is in preclinical growth for addressing RSV, hMPV, and parainfluenza virus sort 3 (PIV3).
Like different proteins, viral antigens should not have a hard and fast form. This instability makes it troublesome to elicit a powerful immune response. Vicebio’s know-how, known as Molecular Clamp, stabilizes viral proteins within the optimum form for the immune system to acknowledge them. Sanofi mentioned it sees the know-how as a option to allow faster growth of totally liquid mixture vaccines that may be saved at customary refrigeration temperatures. This functionality eliminates the necessity for freezing or freeze-drying vaccines, which simplifies vaccine manufacturing and distribution. Additionally, vaccines made with this know-how will also be equipped in prefilled syringes.
“This acquisition furthers Sanofi’s dedication to vaccine innovation with the potential to develop next-generation mixture vaccines that might present safety to older adults in opposition to a number of respiratory viruses with a single immunization,” Jean-François Toussaint, world head of analysis and growth vaccines at Sanofi, mentioned in a ready assertion.
Molecular Clamp relies on analysis from The College of Queensland in Australia. Medicxi licensed rights to the know-how and supplied the founding funding for Vicebio. The startup final raised cash in 2024, a $100 million Collection B financing to help Part 1 testing of VXB-241 for RSV and hMPV. On the time, Vicebio mentioned preliminary knowledge have been anticipated in mid-2025. Up to now, no outcomes have been launched.
Sanofi is already effectively established in in influenza vaccines. It’s attempting to construct on that with next-generation flu pictures primarily based on messenger RNA know-how from its $3.2 billion Translate Bio acquisition in 2021. In RSV, Sanofi is represented by Beyfortus, an FDA-approved antibody drug that works like a vaccine, offering infants and younger youngsters safety from the respiratory pathogen.
The pharma big is pursuing different respiratory pathogens with vaccines primarily based on its mRNA platform. For RSV, SP0125, is presently in Part 2 testing in older adults. SP0256, a bivalent vaccine for RSV and hMPV, is presently in Part 1/2 testing. Additionally in early medical growth is SP0291, an mRNA vaccine for RSV, hMPV, and PIV3. Sanofi mentioned Vicebio’s vaccines complement its pipeline, probably enabling the corporate to supply physicians and sufferers a non-mRNA vaccine possibility.
In a analysis notice, Leerink Companions mentioned the Vicebio acquisition is proof of Sanofi’s enthusiasm for creating protein-based flu vaccines, following its 2024 alliance with Novavax enabling the businesses to develop Covid-19/flu vaccine mixtures. The agency additionally sees the deal as an indication of accelerating M&A exercise sector-wide.
The Vicebio acquisition is anticipated to shut within the fourth quarter of this 12 months, pending buyer closing situations, together with the sign-off from regulators. Sanofi’s different enterprise offers this 12 months embody the $9.5 billion acquisition of immunology medicine developer Blueprint Medicines, which closed final week. Earlier this 12 months, Sanofi paid $470 million to purchase Vigil Neurosciences in addition to $600 million for an early-stage autoimmune illness drug from Dren Bio.
Public area picture by the CDC
